Page 2 - Pharmaceutical Industry

Pharma sees investors cheering bonds, while stocks decline

Pharmaceutical companies have disappointed equity investors on the stock markets in a year that is seeing benchmark indices making new records. On Friday, the Sensex, benchmark index of the BSE, closed at 32,309, a 21.3 per cent gain so far this calendar year. On the other hand, Sun Pharmaceutical, highest vaued Indian entity in the sector, has dropped by 13 per cent to Rs 550 a share on the exchange this year. Similarly, the stock of Glenmark Pharmaceuticals is down by 19 per cent to Rs 717, IPCA Laboratories is down by nine per cent% to Rs 484 and Torrent Pharma is down by five per cent to Rs 1,246.In the same period, corporate bonds of these companies, issued in both the domestic market in rupees and global markets in dollars, have gained. For instance, the yield on Sun Pharmaceutical's corporate bond maturing this December has gone down by 31 basis points (bps) to 6.66 per cent. Bond prices and yield have am inverse relation. As coupon rates (interest to be paid) are decided at ...

Indian firms' drug approvals by US rise 50% in 2017

The growth rate in drug approvals for non-Indian companies is lower at 15.27%

Sakthivel Selvaraj: Fine-tuning drug regulation

The government must ensure that the regulatory architecture governing the pharmaceutical industry widens access to affordable medicines

Drug makers seek policy aid to reduce China reliance

The govt had earlier announced plans to set up bulk drug parks, with a policy to support manufacturing of active pharmaceutical ingredients

Drug firms expect rebound in domestic biz

Firms faced pressure in first quarter due to price cap and drug ban

Ranjit Shahani: Price cap on drugs counterproductive

To ensure equal access to health care, the government must consider it in a holistic manner and improve all parameters